Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease.
Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre.
Adela is initially planning to develop the technology for use for Minimal Residual Disease (MRD) monitoring, followed by Multi-Cancer Early Detection (MCED). Adela’s approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample.
We prioritize the success of the team over individual achievement.
We have the capacity to adapt quickly, navigate uncertainty, and turn failures into opportunities.
We are uncompromising in our adherence to strong ethical principles and values.
We give each other the trust and autonomy to take care of ourselves without compromising our commitments to each other.
We’re open minded and interested in understanding.
The members of Adela’s team are pioneers in the fields of cancer detection, epigenetics and liquid biopsy.
To view additional members of Adela's talented team, visit us on LinkedIn.
Professor, Department of Molecular Genetics at The Donnelly Centre at the University of Toronto
Professor of Medical Oncology at the University of Melbourne, Co-Head of the Cancer Biology & Therapeutics Program and Head of the Molecular Biomarkers & Translational Genomics Laboratory at the Peter MacCallum Cancer Centre
Professor of Epidemiology & Medical Statistics at University College London (UCL), and Director of the Cancer Research UK & UCL Cancer Trials Centre
Professor and Chair of Biomedical Data Science, Professor of Radiology, and Program Director of the Biomedical Informatics Graduate Training Program at Stanford University
Assistant Professor of Biomedical Data Science at Stanford University and Chan-Zuckerberg Investigator